scispace - formally typeset
Patent

Derivatized oligonucleotides having improved uptake and other properties

TLDR
Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, non-aromatic lipophilic molecule, an enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin this article, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties
Abstract
Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2′-position of the functionalized nucleoside via a linking group. If at least a portion of the remaining liked nucleosides are 2′-deoxy-2′-fluoro, 2′-O-methoxy, 2′-O-ethoxy, 2′-O-propoxy, 2′-O-aminoalkoxy or 2′-O-allyloxy nucleosides, the substituent can be attached via a linking group at any of the 3′ or the 5′ positions of the nucleoside or on the heterocyclic base of the nucleoside or on the inter-nucleotide linkage linking the nucleoside to an adjacent nucleoside.

read more

Citations
More filters
Patent

Conjugated 4'-desmethyl nucleoside analog compounds

TL;DR: Tetrahydrofuranyl compounds are provided that are functionalized to include pendant conjugate groups, and which are useful in diagnostic assays and as research reagents.
Patent

Substituted purines and oligonucleotide cross-linking

TL;DR: In this article, purine-based compounds for inclusion into oligonucleotides were proposed, which are especially useful as "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA.
Patent

Devices and methods for biochip multiplexing

TL;DR: In this paper, the authors proposed a method for simultaneous multiple biochip analysis with arrays such as nucleic acid arrays, which allows for high throughput analysis of samples and can be configured to hold multiple cartridges comprising biochips.
Patent

L-ribo-lna analogues

Jesper Wengel
TL;DR: In this paper, a 2'-4'-bridge locks the conformation of the nucleoside with an inverted stereochemistry at C-3' and C-4' to provide the L-ribo-configurated LNA nucleosides.
Patent

RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)

TL;DR: In this article, the authors present methods and reagents useful for modulating gene expression in various applications such as therapeutic, diagnostic, target assessment and genome discovery applications, which relates to synthetic chemically modified small nucleic acid molecules capable of mediating RNA interference (RNAi) to a target NCA sequence, such as short interfering nucleic acids (siNA), short interfering RNA (siRNA).
References
More filters
Journal ArticleDOI

Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis

TL;DR: In this article, the development of a new class of nucleoside phosphites is described, which are stable to normal laboratory conditions, are activated by mild acid treatment, and are observed to react essentially quantitatively with protected nucleosides.
Book

Oligonucleotide synthesis : a practical approach

TL;DR: An introduction to modern methods of DNA synthesis and chromatographic purification of synthetic oligonucleotides is presented.
Journal ArticleDOI

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

TL;DR: The potential use of phosphorothioate oligos as inhibitors of viral replication is highlighted and these are examples of oligos that are being considered for clinical therapeutic trials and meet some, but not all, of these criteria.